{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:42Z","timestamp":1793037642789,"version":"4.5.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Department of the State Administration of Traditional Chinese Medicine - Zhejiang Provincial Administration of Traditional Chinese Medicine Co-construction Key Project","award":["GZY-ZJ-KJ-23093"],"award-info":[{"award-number":["GZY-ZJ-KJ-23093"]}],"id":[{"id":"https:\/\/ror.org\/05c3h8q72","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["Y23H270001"],"award-info":[{"award-number":["Y23H270001"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002418","name":"Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and Peking Union Medical College","doi-asserted-by":"publisher","award":["2021FSYYZZ30"],"award-info":[{"award-number":["2021FSYYZZ30"]}],"id":[{"id":"10.13039\/501100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2025KY315"],"award-info":[{"award-number":["2025KY315"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Osteoarthritis (OA) as a degenerative disease, has seen a continuous rise in incidence and prevalence globally since 1990, imposing a significant disease burden. NSAIDs (Nonsteroidal anti-inflammatory drugs) as symptomatic medications for OA treatment, hold an indispensable position in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of different NSAIDs in the treatment of OA through Bayesian Network Meta-Analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) on NSAIDs for OA treatment were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library databases. The search timeframe was from the inception of each database up to June 1, 2024. Outcome indicators for NMA were all conducted using a random-effects model. MetaInsight and Stata 14.0 software were used in R for calculations and plotting of NMA. Measurement data were represented by mean difference (MD), and count data by odds ratio (OR); a 95% confidence interval (CI) was also calculated for each effect size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 31 studies, involving 68,539 patients with knee osteoarthritis (KOA) and 16 interventions. NMA results showed that compared to the placebo, Tiaprofenic reduced the VAS score (MD =\u2009 -0.16, 95% CI: (-0.46 to 0.14), P &gt;\u2009 0.05), albeit without significant difference; meanwhile, Diclofenac reduced the total WOMAC score in KOA patients (MD =\u2009 -0.41, 95% CI: -1.05 to 0.24, P &gt;\u2009 0.05). Compared to the placebo, Etoricoxib was the best medication for improving the WOMAC pain subscale score (MD =\u2009 -0.44; 95% CI: -0.61 to -0.26); Naproxen significantly improved the WOMAC Function score in KOA patients after administration (MD = -0.43; 95% CI: -0.82 to -0.04); Diclofenac intervention significantly reduced the WOMAC Stiffness score in KOA patients (MD =\u2009 -0.40; 95% CI: -0.67 to -0.13). In terms of adverse event rates, compared to the placebo, the use of Etoricoxib significantly increased the incidence of cardiovascular adverse events (OR =\u2009 0.56, 95% CI: 0.32\u20130.99); Ketoprofen had fewer gastrointestinal adverse events during the medication process (OR =\u2009 0.09, 95% CI: 0.04\u20130.20); Licofelone had a lower rate of other adverse events during the medication process (OR =\u2009 0.80, 95% CI: 0.45\u20131.40, P &gt;\u2009 0.05). Therefore, the results indicate that Etoricoxib, Tiaprofenic, Naproxen, Diclofenac, and Ketoprofen have better clinical efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to other NSAIDs, Etoricoxib, Tiaprofenic, Naproxen, and Diclofenac play a more effective role in improving clinical symptoms of OA; in terms of reducing the incidence of adverse events, Ketoprofen has a lower chance of adverse events. However, the possibility of these results still needs further clinical and basic research for verification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0320379","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:30:31Z","timestamp":1746624631000},"page":"e0320379","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Assessing the efficacy and safety of different nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: A systematic review and network meta-analysis based on RCT trials"],"prefix":"10.1371","volume":"20","author":[{"given":"Pan","family":"JiaoYi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"YongQi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"KeChun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9832-9011","authenticated-orcid":true,"given":"Li","family":"XingYu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"ZeZhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Jin Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"YouJia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Bing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3927-1049","authenticated-orcid":true,"given":"Wang","family":"XiaoFeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"1","key":"pone.0320379.ref001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/0115680266297662240527105450","article-title":"Role of plant materials with anti-inflammatory effects in phytotherapy of osteoarthritis","volume":"25","author":"M Geszke-Moritz","year":"2025","journal-title":"Curr Top Med Chem"},{"issue":"26","key":"pone.0320379.ref002","doi-asserted-by":"crossref","first-page":"18296","DOI":"10.1039\/D4RA02780A","article-title":"Ursolic acid inhibits NF-\u03baB signaling and attenuates MMP-9\/TIMP-1 in progressive osteoarthritis: a network pharmacology-based analysis","volume":"14","author":"EM Zahran","year":"2024","journal-title":"RSC Adv"},{"issue":"1","key":"pone.0320379.ref003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMcp1903768","article-title":"Osteoarthritis of the knee","volume":"384","author":"L Sharma","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0320379.ref004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acr2.11235","article-title":"The role of knowledge and attitudes about nonsteroidal anti-inflammatory drugs in determining treatment use","volume":"3","author":"ER Vina","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"pone.0320379.ref005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13075-021-02524-9","article-title":"Opioid users show worse baseline knee osteoarthritis and faster progression of degenerative changes: a retrospective case-control study based on data from the Osteoarthritis Initiative (OAI)","volume":"23","author":"J Bodden","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"8982","key":"pone.0320379.ref006","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(95)91782-9","article-title":"NSAIDs, Cox-2 inhibitors, and the gut","volume":"346","author":"A Bennett","year":"1995","journal-title":"Lancet"},{"issue":"3","key":"pone.0320379.ref007","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bcpt.12527","article-title":"Acetaminophen for chronic pain: a systematic review on efficacy","volume":"118","author":"ZN Ennis","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"pone.0320379.ref008","first-page":"244","article-title":"Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy","volume":"35","author":"PA Todd","year":"1988","journal-title":"Drugs"},{"key":"pone.0320379.ref009","volume-title":"Goodman & Gilman\u2019s: the pharmacological basis of therapeutics","author":"LL Brunton"},{"issue":"1","key":"pone.0320379.ref010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40001-015-0115-7","article-title":"Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis","volume":"20","author":"J Kongtharvonskul","year":"2015","journal-title":"Eur J Med Res"},{"issue":"5","key":"pone.0320379.ref011","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2013.10.002","article-title":"Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis","volume":"43","author":"RR Bannuru","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"pone.0320379.ref012","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2036.2005.02383.x","article-title":"Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis","volume":"21","author":"GM Eisen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0320379.ref013","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"pone.0320379.ref014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1063-4584(02)00353-9","article-title":"Arthroscopic evaluation of potential structure-modifying drug in osteoarthritis of the knee. A multicenter, randomized, double-blind comparison of tenidap sodium vs piroxicam","volume":"11","author":"X Ayral","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"pone.0320379.ref015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12891-016-1170-0","article-title":"Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial","volume":"17","author":"K Bickham","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"pone.0320379.ref016","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/kel296","article-title":"Efficacy and safety of etoricoxib 30\u2009mg and celecoxib 200\u2009mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies","volume":"46","author":"3rd Bingham CO","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pone.0320379.ref017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1185\/030079906X80242","article-title":"Efficacy and safety of rofecoxib 12.5\u2009mg and celecoxib 200\u2009mg in two similarly designed osteoarthritis studies","volume":"22","author":"C Birbara","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"9549","key":"pone.0320379.ref018","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"368","author":"CP Cannon","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"pone.0320379.ref019","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","article-title":"Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group","volume":"43","author":"GW Cannon","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pone.0320379.ref020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.163.2.169","article-title":"Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium","volume":"163","author":"JP Case","year":"2003","journal-title":"Arch Intern Med"},{"key":"pone.0320379.ref021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2474-6-58","article-title":"Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]","volume":"6","author":"SP Curtis","year":"2005","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"pone.0320379.ref022","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/147323001204000414","article-title":"Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial","volume":"40","author":"MN Essex","year":"2012","journal-title":"J Int Med Res"},{"issue":"1","key":"pone.0320379.ref023","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10067-005-1126-5","article-title":"Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib","volume":"25","author":"R Fleischmann","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"1","key":"pone.0320379.ref024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2014-206792","article-title":"Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib","volume":"75","author":"MC Hochberg","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"pone.0320379.ref025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/art.1780360904","article-title":"Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee","volume":"36","author":"HJ Williams","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pone.0320379.ref026","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/147323000102900602","article-title":"Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip","volume":"29","author":"AJ Kivitz","year":"2001","journal-title":"J Int Med Res"},{"issue":"8","key":"pone.0320379.ref027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1742-1241.2001.tb11112.x","article-title":"Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis","volume":"55","author":"W Kriegel","year":"2001","journal-title":"Int J Clin Pract"},{"issue":"3","key":"pone.0320379.ref028","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/ard.2007.082388","article-title":"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)","volume":"67","author":"K Krueger","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pone.0320379.ref029","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1185\/030079905X38196","article-title":"Efficacy and tolerability of lumiracoxib 100\u2009mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib","volume":"21","author":"R Lehmann","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"pone.0320379.ref030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079902125000282","article-title":"Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial","volume":"18","author":"AT Leung","year":"2002","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"pone.0320379.ref031","doi-asserted-by":"crossref","first-page":"M167-75","DOI":"10.1093\/gerona\/56.3.M167","article-title":"Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib","volume":"56","author":"J Lisse","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"pone.0320379.ref032","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/ard.2008.088732","article-title":"Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI","volume":"68","author":"J-P Raynauld","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"pone.0320379.ref033","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.2006.059162","article-title":"Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis","volume":"66","author":"JY Reginster","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pone.0320379.ref034","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/ard.2009.120469","article-title":"Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT","volume":"69","author":"AD Sawitzke","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0320379.ref035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clinthera.2005.01.002","article-title":"Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo","volume":"27","author":"E Sheldon","year":"2005","journal-title":"Clin Ther"},{"issue":"4","key":"pone.0320379.ref036","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/art.40400","article-title":"Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: a randomized clinical trial","volume":"70","author":"DH Solomon","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"pone.0320379.ref037","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/ard.2003.015974","article-title":"Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib","volume":"63","author":"H Tannenbaum","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0320379.ref038","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clinthera.2006.02.004","article-title":"Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis","volume":"28","author":"AR Temple","year":"2006","journal-title":"Clin Ther"},{"issue":"2","key":"pone.0320379.ref039","first-page":"112","article-title":"A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis","volume":"13","author":"KE Truitt","year":"2001","journal-title":"Aging (Milano)"},{"issue":"1","key":"pone.0320379.ref040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.rhu.0000200384.79405.33","article-title":"Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone","volume":"12","author":"AL Weaver","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"pone.0320379.ref041","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclooxygenase-2\u2013specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"A Whelton","year":"2001","journal-title":"Am J Ther"},{"issue":"4","key":"pone.0320379.ref042","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.mjt.0000127360.23508.04","article-title":"Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis","volume":"11","author":"WB White","year":"2004","journal-title":"Am J Ther"},{"issue":"12","key":"pone.0320379.ref043","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1185\/03007995.2014.955169","article-title":"Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial","volume":"30","author":"MC Yoo","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"pone.0320379.ref044","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/ket133","article-title":"A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis","volume":"52","author":"PG Conaghan","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"pone.0320379.ref045","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/bjsports-2017-098043","article-title":"Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies","volume":"52","author":"C Zeng","year":"2018","journal-title":"Br J Sports Med"},{"issue":"18","key":"pone.0320379.ref046","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2165\/00003495-200262180-00006","article-title":"Etoricoxib","volume":"62","author":"DJ Cochrane","year":"2002","journal-title":"Drugs"},{"issue":"3","key":"pone.0320379.ref047","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2165\/00003495-198529030-00002","article-title":"Tiaprofenic acid. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases and pain states","volume":"29","author":"EM Sorkin","year":"1985","journal-title":"Drugs"},{"issue":"Suppl 1","key":"pone.0320379.ref048","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40266-019-00664-x","article-title":"Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis","volume":"36","author":"E Curtis","year":"2019","journal-title":"Drugs Aging"},{"issue":"5","key":"pone.0320379.ref049","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/000164701753532844","article-title":"The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis","volume":"72","author":"H Uzun","year":"2001","journal-title":"Acta Orthop Scand"},{"issue":"2","key":"pone.0320379.ref050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/17425255.1.2.269","article-title":"Clinical pharmacology of etoricoxib","volume":"1","author":"ML Capone","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"pone.0320379.ref051","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/psm.2010.06.1779","article-title":"Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial","volume":"38","author":"HSB Baraf","year":"2010","journal-title":"Phys Sportsmed"},{"issue":"5","key":"pone.0320379.ref052","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/00480169.2010.69295","article-title":"A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: haematological, biochemical and pathological findings","volume":"58","author":"AA Mozaffari","year":"2010","journal-title":"N Z Vet J"},{"issue":"11","key":"pone.0320379.ref053","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"RS Bresalier","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0320379.ref054","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2340\/00015555-1855","article-title":"Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study","volume":"95","author":"S Wu","year":"2015","journal-title":"Acta Derm Venereol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:30:44Z","timestamp":1746624644000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320379"}},"subtitle":[],"editor":[{"given":"Ma \u00c1ngeles","family":"Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0320379","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}